Posted: Thursday, January 19, 2023
In the Journal of Cancer Prevention, researchers provided significant data about molecular targets of the jaboticaba peel extract (from a Brazilian berry) and its mechanisms of action in prostate cancer cell lines with different androgenic status (androgen-sensitive LNCaP cells and PC-3 cells that do not express androgen receptor). Jaboticaba peel extract was found to be able to decrease cell viability in both cell lines, with LNCaP cells showing more sensitivity to exposure to this extract. The results in this study confirmed that jaboticaba peel extract may be an NF-κB pathway inhibitor, especially in androgen-dependent cells.
“[Jaboticaba peel extract] exerted an antitumor effect on [prostate cancer] for both cell lines [that] can be enhanced if androgenic reliance is considered,” stated Larissa Akemi Kido, PhD, of the University of Campinas, São Paulo, and colleagues reported.
In this study, LNCaP and PC-3 cells were exposed to various concentrations of jaboticaba peel extract for different time periods. This determined the most optimal experimental conditions, which can decrease the viability of both lines in dose- and time-dependent manners. LNCaP cells proved to be more sensitive to jaboticaba peel extract exposure, showing a significant reduction in their viability, even at the lowest dose, after 24 hours of treatment. The maximum effect of jaboticaba peel extract on LNCaP viability was verified after 48 hours. However, after 72 hours, only the highest dose was able to reduce cell viability.
The PC-3 viability was significantly inhibited by jaboticaba peel extract after 24 hours and 48 hours at the 500 µg/mL concentration. After 72-hour exposure, all doses were able to significantly reduce the PC-3 cell viability.
These results suggest that the efficacy of jaboticaba peel extract treatment could be related to the androgen-responsive status of human prostate cancer cells. This is shown by the early response of LNCaP at lower doses of jaboticaba peel extract and the less-sensitive late response of PC-3 cells.
Disclosure: The study authors reported no conflicts of interest.